Compare MMA & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MMA | OSRH |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Australia | United States |
| Employees | N/A | 21 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 11.7M |
| IPO Year | 2023 | N/A |
| Metric | MMA | OSRH |
|---|---|---|
| Price | $0.43 | $0.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 333.0K | ★ 714.2K |
| Earning Date | 05-20-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.38 |
| 52 Week High | $2.88 | $1.79 |
| Indicator | MMA | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 51.86 |
| Support Level | $0.35 | $0.41 |
| Resistance Level | $0.50 | $0.74 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 36.40 | 50.65 |
Mixed Martial Arts Group Ltd is a technology company operating in the martial arts and combat sports industry. The company operate four core business units: i) TrainAlta: A platform that transforms MMA fans into active participants through structured training programs like the Warrior Training Program, ii) BJJLink: A gym management platform designed for BJJ academies, offering tools for payment processing, marketing, student engagement, and content monetization, iii) Hype: A marketing platform helping gym owners, coaches, and athletes grow revenue from their audiences, iv) MixedMartialArts.com: The go-to resource for MMA news, fighter data, fight schedules, and the legendary Underground forum. Its majority of revenue is in the form of Program revenue, which consists of the license fees.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.